Investing in Curis, Inc. (CRIS)  ➔  Intrinsic value

Prev. close$7.60 
Previous Close$7.60  
Valuation MethodValuePotential 
Chepakovich Model$1.30-83%recalculate
Graham Formula$0.00-100%recalculate

Latest news

Company description

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation; and Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors. The company's products in pipeline include CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and DarwinHealth, Inc. to characterize biomarkers and tumor subtype alignments to identify therapeutic opportunities. The company was founded in 2000 and is headquartered in Lexington, Massachusetts.